COMPARATIVE MOLECULAR DOCKING STUDIES OF 7-HYDROXY COUMARIN DERIVATIVES

TYAGI ALKA; SADGIR PRIYANKA

doi:10.22159/ijpps.2025v17i9.54600

Authors

TYAGI ALKA Department of Pharmaceutical Chemistry, Banasthali Vidyapith, Rajasthan, India
SADGIR PRIYANKA Department of QA, Shri. Pandit Baburao Chughule College of Pharmacy, Thane, India

DOI:

https://doi.org/10.22159/ijpps.2025v17i9.54600

Keywords:

Alzheimer’s disease, Docking, In silico, Coumarin, AChE, 7-hydroxy coumarin

Abstract

Objective: The derivatives of 7-hydroxycoumarin were studied as novel human acetylcholinesterase (AChE) inhibitors that could be useful in the treatment of Alzheimer's disease (AD).

Methods: This study set out to determine the lead molecules (synthesized 7-hydroxycoumarin derivatives) and investigate the viability of two distinct docking strategies for our target AChE: Auto Dock vina and Schrodinger Glide. Using these tools, we have conducted a comparative analysis of ligand binding affinity and binding poses.

Results: Among all the Coumarin-derived compounds docked against hAChE, 2 compounds, namely, 2-((2-oxo-2H-chromen-4-yl) oxy)-N-(pyridin-3-yl) acetamide derivative 4(d) and 7-(2-oxo-2-(10 H-phenothiazin-10-yl) ethoxy)-2H-chromen-2-one, 4(f) showed the best docking results.

Conclusion: Schrodinger was found to be comparatively more helpful in blind docking pose prediction and consistently outperformed another program. In the current study, the most powerful compound’s interactions with amino acids in binding pockets are analysed and compared using both docking tools.

Downloads

Download data is not yet available.

References

1. Dorababu A. Promising heterocycle-based scaffolds in recent (2019-2021) anti-Alzheimer’s drug design and discovery. Eur J Pharmacol. 2022 Apr 5;920:174847. doi: 10.1016/j.ejphar.2022.174847, PMID 35218718.

2. Kulisevsky J. Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson’s disease. Drugs Aging. 2000;16(5):365-79. doi: 10.2165/00002512-200016050-00006, PMID 10917074.

3. Sharma P, Srivastava P, Seth A, Tripathi PN, Banerjee AG, Shrivastava SK. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies. Prog Neurobiol. 2019 Mar;174:53-89. doi: 10.1016/j.pneurobio.2018.12.006, PMID 30599179.

4. Tyler CR, Allan AM. The effects of arsenic exposure on neurological and cognitive dysfunction in human and rodent studies: a review. Curr Environ Health Rep. 2014;1(2):132-47. doi: 10.1007/s40572-014-0012-1, PMID 24860722.

5. Choubdar N, Golshani M, Jalili Baleh L, Nadri H, Kucukkilinc TT, Ayazgok B. New classes of carbazoles as potential multi-functional anti-Alzheimer’s agents. Bioorg Chem. 2019 Oct;91:103164. doi: 10.1016/j.bioorg.2019.103164, PMID 31398601.

6. Rani P, Singh K, Arjuna A, Devi S. Genetic disorder Alzheimer. Asian J Pharm Clin Res. 2017;10(12):36-9. doi: 10.22159/ajpcr.2017.v10i12.18684.

7. Tham W, Auchus AP, Thong M, Goh ML, Chang HM, Wong MC. Progression of cognitive impairment after stroke: one-year results from a longitudinal study of singaporean stroke patients. J Neurol Sci. 2002;203-204(6):49-52. doi: 10.1016/s0022-510x(02)00260-5, PMID 12417356.

8. Tripathi PN, Srivastava P, Sharma P, Tripathi MK, Seth A, Tripathi A. Biphenyl-3-oxo-1,2,4-triazine-linked piperazine derivatives as potential cholinesterase inhibitors with anti-oxidant property to improve the learning and memory. Bioorg Chem. 2019 Apr;85:82-96. doi: 10.1016/j.bioorg.2018.12.017, PMID 30605887.

9. Piplani P, Danta CC. Design and synthesis of newer potential 4-(N-acetylamino) phenol-derived piperazine derivatives as potential cognition enhancers. Bioorg Chem. 2015 Jun;60:64-73. doi: 10.1016/j.bioorg.2015.04.004, PMID 25965977.

10. Sharma V. Alzheimer’s disease: a consequence of impaired mitophagy? Asian J Pharm Clin Res. 2019;12(2):75-80. doi: 10.22159/ajpcr.2019.v12i2.28407.

11. Korolev IO. Alzheimer’s disease: a clinical and basic science review. Med Student Res J. 2014 Sep;4:24-33.

12. Yusufzai SK, Khan MS, Sulaiman O, Osman H, Lamjin DN. Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and β-amyloid inhibitors for Alzheimer’s disease. Chem Cent J. 2018;12(1):128. doi: 10.1186/s13065-018-0497-z, PMID 30515636.

13. Sirvio J, Riekkinen P, Jakala P, Riekkinen PJ. Experimental studies on the role of serotonin in cognition. Prog Neurobiol. 1994;43(4-5):363-79. doi: 10.1016/0301-0082(94)90060-4, PMID 7816931.

14. Blokland A. Acetylcholine: a neurotransmitter for learning and memory? Brain Res Brain Res Rev. 1995;21(3):285-300. doi: 10.1016/0165-0173(95)00016-x, PMID 8806017.

15. Shi DH, Min W, Song M, Si XX, Li MC, Zhang Z. Synthesis, characterization crystal structure and evaluation of four carbazole coumarin hybrids as multifunctional agents for the treatment of Alzheimer’s disease. J Mol Struct. 2020 Jun 5;1209:127897. doi: 10.1016/j.molstruc.2020.127897.

16. Hu YH, Yang J, Zhang Y, Liu KC, Liu T, Sun J. Synthesis and biological evaluation of 3-(4-aminophenyl)-coumarin derivatives as potential anti-Alzheimer’s disease agents. J Enzyme Inhib Med Chem. 2019;34(1):1083-92. doi: 10.1080/14756366.2019.1615484, PMID 31117844.

17. Piazzi L, Cavalli A, Colizzi F, Belluti F, Bartolini M, Mancini F. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett. 2008;18(1):423-6. doi: 10.1016/j.bmcl.2007.09.100, PMID 17998161.

18. Makhaeva GF, Shevtsova EF, Boltneva NP, Lushchekina SV, Kovaleva NV, Rudakova EV. Overview of novel multifunctional agents based on conjugates of γ-carbolines carbazoles tetrahydrocarbazoles, phenothiazines and aminoadamantanes for treatment of Alzheimer’s disease. Chem Biol Interact. 2019 May;308:224-34. doi: 10.1016/j.cbi.2019.05.020, PMID 31100279.

19. Zheng H, Fridkin M, Youdim M. From single target to multitarget/network therapeutics in Alzheimer’s therapy. Pharmaceuticals (Basel). 2014;7(2):113-35. doi: 10.3390/ph7020113, PMID 24463342.

20. Terry RD, Gonatas NK, Weiss M. Ultrastructural studies in Alzheimer’s presenile dementia. Am J Pathol. 1964;44(2):269-97. PMID 14119171.

21. Walhekar VM, Bathe V, Kadam V, Rokade S. Review on Embelia ribes and it’s pharmacological activity. International Journal of Pharmaceutical Sciences. 2024;2(4):1312-9. doi: 10.5281/zenodo.11092906.

22. Bhawana S, Alka T, Anurag. Design creation and biological screening of newer coumarin-coupled heterocyclic hybrids as acetylcholinesterase inhibitors that may be useful in the treatment of Alzheimer’s disease. Pharm Chem J. 2024;58(7):1069-83. doi: 10.1007/s11094-024-03245-4.

23. Kono Y. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys. Science Direct. 1978;186(1):189-95. doi: 10.1016/0003-9861(78)90479-4, PMID 24422.

24. Azam SS, Abbasi SW. Molecular docking studies for the identification of novel melatoninergic inhibitors for acetylserotonin-O-methyltransferase using different docking routines. Theor Biol Med Model. 2013 Oct 24;10:63. doi: 10.1186/1742-4682-10-63, PMID 24156411.

25. Sharma P, Tripathi A, Tripathi PN, Singh SS, Singh SP, Shrivastava SK. Novel molecular hybrids of N-Benzylpiperidine and 1,3,4-oxadiazole as multitargeted therapeutics to treat Alzheimer’s disease. ACS Chem Neurosci. 2019;10(10):4361-84. doi: 10.1021/acschemneuro.9b00430, PMID 31491074.

26. Silva MA, Kiametis AS, Treptow W. Donepezil inhibits acetylcholinesterase via multiple binding modes at room temperature. J Chem Inf Model. 2020;60(7):3463-71. doi: 10.1021/acs.jcim.9b01073, PMID 32096991.